ArriVent Biopharma paid $47m to license MRG007, a Phase 1-ready gastrointestinal cancer therapy developed by Shanghai’s Lepu Biopharma. The antibody drug conjugate has not had its target disclosed but ArriVent said studies showed it had “best-in-class potential”, and suggested it could be a drug that targets claudin 18.2. ArriVent said MRG007 displayed strong anti-tumour action in preclinical models, with the first submissions expected in H1 2022.
Sonatype reports rise in open source malware to 17,954
The 1Q 2025 Open Source Malware Index from Sonatype revealed that open source malware packages doubled compared to the same period last year, with 56%
